Good like first Jeannie. quarter and everyone. to you, results afternoon afternoon, joining summary I’d for our of Thank begin Thank this us today. you with the call milestones.
COVID-XX deliberate to to and and to Next, we’ve the balance cash order commercial the to of our sheet. outline costs reduce I’d like strengthen throughout significantly in organization, discuss impact the executed actions cut burn
as as our the clinical outline our provide important our to forward. of upcoming business like going SUI I’d for development program, Finally, trajectory perspective and highlight well milestones the
physician The show continuing demonstrated of increase started XXXX quarter traction, model To rates momentum was perspective. building costs and adoption, new clinical, commercial, begin, was quarter. by to a well to into regulatory barriers designed upfront our U.S. and to financial adoption revenue reducing the strength from recurring effectiveness that a and with
physician success early in growing the Armed initial with commercial marketing increasing confirmation we support of within the our began customer program model’s and scale departments. enthusiasm, quarter the to U.S. sales, and the steps
this June It can XXXX scale, flow designed rapid to and scalability. breakeven. As more provide of quarterly revenue quickly for previously sales, believe lower with growth improve profitability. in provide revenue greater lead At predictable per implemented the cash was was and improved model this company from stated, selling costs, to model annual sales consumable customer, we us long-term
to sales end As the a the the recurring the former company. was realized of this be from change of its February through massive the model to revenue year. were capital for U.S. the results reminder, a And continuing model transformation in
effects disruptive experience in commercial to we the However, began directly the March, pandemic. coronavirus of
in we been XXX of had of XX, revenue impact installed revenue commercial the company worldwide, total them XXXX, U.S., million. Systems the QX, base are model. reporting March recurring which an under XXX the Viveve of $X.X of the placed XX Despite And in of as had
throughout treatment over than our next our for a X.X and XX the achievement company’s system, to key X.X tips in testament Taiwan, tips Manufactured North lower global consumable reported. countries. at clearances of quarter, in Asia a generation were a regulatory European first significantly Viveve now in are the and continuing platform America, clearances and during are milestones. front Canada regulatory cost and the first available These generation system the On treatment commercially market
a preceded and readout sexual This milestones achieve function U.S. significant also our the SUI progress, demonstrating not Sexual with did early XX efficiency. short-term of as total in development from reported months. endpoint top-line unfortunately, in or Index stress the statistically Function mean significant the April, meet Female we urinary improvement the VIVEVE study our And II however, clinical clinical its X-arm incontinence at in baseline QX, of trial. study, program advanced In that change primary in feasibility timely our
in sufficient sham improvement treatment hour, statistically substantial there active was from the the not separation was demonstrated significant study group. there Although
a near-term As continuing market resources has program. of on and I’ll strategic clinical discuss evidence, business dollar a focus advancing benefits the in of studies with detail few CMRF to commercially the potential multiple to development treatment, realize and decision our in resulted our efforts in multi-billion through and opportunity all minutes, both our associated SUI enduring our consumable company’s
to the companies Next, executed in burn, the deliberate unprecedented market balance to impact in to strengthen discuss the all throughout swiftly significantly and I’d resulting to like discuss the costs of from like order our had cash the industries of economic health, to sheet. and organization COVID-XX COVID-XX respond actions and crisis. majority cut Viveve we’ve commercial reduce challenges
response and organizational our summarize then provide first me Let some detail.
and we beginning changes, employees, safety of financial restrictions and organization necessary. contacts and company’s our protect lift an commercial in majority health despite implemented other of to response. and partners customers, to First, The cities health of support our range The are urgent a likewise that states. distribution continues the some required business as remotely, designed operational work to and
to were in resources to development and our and As expenses April, our cost stress reported a reposition program urinary customers of actions of drastically in series treatment significant support current incontinence. clinical implemented the pivotal cutting reduce
the our sales improve. as rescale quickly Although realignment full cutting expense and growth reductions, resume team actions operations and ability we to conditions commercial retained and have extensive staff involve
actions successful long-term the The that evolve. strategy coming we ultimate business provided preserve sheet warrant the transaction our necessary of the resources months important crisis and existing the exercise recently as in maintain to the advance that Viveve’s goal SUI taken continues to balance have clinical and program announced, was value to company. is strengthened combined the have the COVID-XX for with Additionally, development cash, and create has
services to staff XX% of their and practices our of U.S. or temporarily This practices. or same XX% medical made In targeted with customers April, approximately was dramatically significant. commercial a were our prospective physician And either to and reductions organization existing the and reducing customers. result closing
to of and effort COVID-XX elective public and combat orders stay-at-home coronavirus hold protect result know, health to an directives treatments of and the you this safety. and the in procedures spread medical was As non-essential a
improve. to We organization, ensure commercial significantly as new done a existing anticipate the reduced refocused concerns customers. and are and prospective but result temporarily operations to partial were ability subscription of customers that of to abates, number team full we’re revenue reduced when commercial elective reductions to begin will help as and As rescale and support rapidly greatly furloughs existing pandemic safety to reduced The and practices conditions the customers. COVID-XX that we reopen, the until experience from continue well a as patient reduced, our
talented means. care and on of commercial are our our in However, a support the variety marketing customers and existing of through focused practitioners customer teams new digital engaging meantime, with
are prospects. University, marketing and programs available formats participation Viveve and practice virtual development with Our and existing fact targeted record-high in customers now is in physician a level at
and using activities procedures changes confident treatment practitioners our made cash. resources of help are to U.S. the elective commercial volumes will build we that and advantage Overall, practices to forced take as costs are the preserve support their downtime restart. recent Many customers, educational in reduce our support will that
products without international significant continues business our by change United partners the of model. outside distribution States supported to the to current the be Sale company’s
on the in the in and countries since has Asia. focus predominant second half of XXXX growing business key been Our regions
to this As physician the anticipate through recovery. we in countries quarter, utilization we of thankfully, Asia showing epicenter Currently, year. coronavirus. coming signs and near-normal was of know, commercial region return a have the the But distributor initially been activity and the sales remainder within of the
However, U.S. customers to markets less efforts rates. somewhat existing And elective of we continue Europe throttle are health support COVID-XX and in global distributors patients’ as to other speed as pre-COVID recovery return may in continuing and and concerns advanced. the safety procedure the
urinary million an a worldwide, will going $XX for billion to million is program. available condition technology like address believe clinical women development we the and company our represents affects and advancement set course near-term CMRF this of the billion of our in now that XX I’d $XX the program stress opportunity. market SUI to forward. estimated achievement that the consumable XX a is total key milestones It Finally, incontinence to
X clinical SUI studies symptoms that reduces the Viveve demonstrated for safely improves treatment leakage previous in women. and have We
the to positive. resolute which as focus, if organization of for targeted SUI which trial the complete in Our now SUI our feasibility resubmitted begin achieve was the study PURSUIT the practicable two, year; soon readout trial, IDE X-arm U.S. study entire feasibility of one, April, and FDA is this repositioned, clearance for has the as to summer is and to: been late
in SUI XX to is arms. subjects on at approximately treatment treatment current ratio each women. a inert single-blind SUI X sites of sham with randomized treatment study our prospective planned clinical sham X-arm a improvement The being one-to-one-to-one CMRF in for of of a to enrollment and feasibility the a totally Canada study The conducted X randomized study compares cryogen-only
A endpoint X is The between trial of our the States. data short placebo support readout sham of would The separation at months of to weight United is and goal initiation post-treatment. baseline efficacy the the in study. from pivotal in directional X-hour trial the inert feasibility change pad arm test the positive or mean standard study primary arms, the this from primary true demonstrate treatment strongly the PURSUIT
the study, Investigational trial was performing approved and Testing medical enrollment March timing COVID-XX completed procedures. Health a feasibility Fortunately, non-essential before initiated medical from shut by Canada, perspective, in Application centers from down the
final to time will resume reduce We measures initiated and better more this compliance with change COVID-XX a safety and have any We patient services also enacted to that subjects’ health the the X follow-up deviations. investigational This support anticipate with visits minimize from X concerns. protocol patient potential will visit sites months. X-month to provide final also extension medical for follow-up the
is As milestone readout year, represents late of Viveve. study the stated, a clinical targeted major this SUI feasibility and previously in for final for the summer the
in of word readout commitment approval company the In pivotal for CMRF FDA SUI of enable our to of represented the Moving IDE rigor, study, our continue importance label implications of and a to PURSUIT positive U.S. this its pending design U.S. future keeping for expansion are study, indication. an for the PURSUIT the meaning our of SUI initiation technology trial, its the will by U.S. feasibility the scientific strategic this with trial, PURSUIT. to the and
the at the the for to The up Again, post-treatment. endpoint States. sites weight United Enrollment in test IDE intended set to primary is sham-controlled be double-blind resubmitted multicenter, to a intended the XXX pad the PURSUIT trial in to be months randomized, patients X-hour study approximately is FDA XX XX trial. efficacy proposed April, is
receive now the of joules per Subjects treatment X-to-X clinically cryogen of XX sham CMRF of PURSUIT arm treatments active the a centimeter in control less arm squared treatment cooling control ratio, me for than will the active cooling. in centimeter group treatment and Randomized in a subjects this the receive than this to will RF X inert It’s important trial. and of degrees squared less radiofrequency cryogen. per X comparative tissue joule for in emphasize in
cooling underway induce trials, treatment currently and subclinical or thereby a by treatment The in cryogen control be not and inert the true group treatment will Unlike tip sham should group. at the the the previous will in a minimal control response therapeutic be the energy SUI of subjects Viveve feasibility the and in sham with RF levels, clinically the delivered study, administered clinical exception be sham will that treatment.
inert the is pad PURSUIT FDA of active And target for trial Viveve’s the group, in weight treatment year. in treatment anticipated design, in of test. fall this standardized sham SUI IDE the objective the approval the highly By an X-hour will powered group control the the pending to compare using initiation, CMRF
for positive separation arms the challenges sham and in from feasibility trial ability and Viveve uncertain energy SUI SUI remains of health spite In in positive true confidence to unprecedented the duration will study X importance or readout upcoming A of caused crisis, economic SUI and the paramount. the potential clinical positions a between results showing directional the the and achieve the our of COVID-XX placebo the indication. milestones provide of program PURSUIT arm inner U.S. the
breadth actions burn, cash COVID-XX and cut reduce of imperative costs, the the organization to severe, Although for resources the and to refocus were taken the crisis. magnitude company survive reposition the
pandemic. to I and As of team our these a are we company address measures, to successfully to continued and adapt face the result and talented and containment this cost actions, diligence continue challenges will believe the from with
of continued successfully united the Viveve. our support existing are perseverance We the our to and that in focus is hallmark to that proud so of will achieve upcoming commercial And in our clinical dedication SUI. milestones efforts I’m the advance customers.
has wellness. always and the innovator vision and Our in been intimate remains leader global and women’s be to health
quarter I’d is in prepared today. Operator, our our participating of everyone thank call for remarks. end first the like to this conference
